|本期目录/Table of Contents|

[1]郑竹影,孙艳,程静波,等.突变型P53特异性活化T细胞的诱导与扩增[J].浙江理工大学学报,2014,31-32(自科6):678-684.
　ZHENG Zhu ying,SUN Yan,CHENG Jing bo,et al.Induction and Amplification of Mutant P53 Specific Activated T Cells[J].Journal of Zhejiang Sci-Tech University,2014,31-32(自科6):678-684.
点击复制

突变型P53特异性活化T细胞的诱导与扩增()
分享到：

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第31-32卷
期数:
2014年自科6期
页码:
678-684
栏目:
(自科)生物与生命科学
出版日期:
2014-11-10

文章信息/Info

Title:
Induction and Amplification of Mutant P53 Specific Activated T Cells
文章编号:
1673-3851 (2014) 06-0678-07
作者:
郑竹影;  孙艳;  程静波;  钱其军
1. 浙江理工大学生命科学学院新元医学与生物技术研究所, 杭州 310018;2. 第二军医大学东方肝胆外科医院病毒基因治疗实验室, 上海 200438
Author(s):
ZHENG Zhuying;  SUN Yan;  CHENG Jingbo;  QIAN Qijun
1. Xinyuan Institute of Medicine and Biotechnology, School of Life Science, Zhejiang SciTech University,Hangzhou 310018, China; 2.Laboratory of Virus and Gene Therapy, Eastern Hepatobiliary Surgical Hospital,Second Military University, Shanghai 200438, China
关键词:
多因子诱导;  树突状细胞;  特异性活化T细胞;  扩增
分类号:
R392.12
文献标志码:
A
摘要:
采用多种细胞因子诱导外周血单核细胞分化为成熟的树突状细胞(DC,Dentritic Cell),将成熟DC与初始T细胞共培养,并连续加入DC刺激从而避免活化的T细胞凋亡。将活化的T细胞转入包被有CD3和CD28抗体的板中,使活化T细胞进一步大量扩增。流式检测多因子诱导后DC表型发现,高表达CD83、CD11c、CD11b、CD80、CD86、CCR7、CD54,低表达CD14、CD3、CD33,说明因子成功诱导单核细胞为成熟DC。流式检测扩增的活化T细胞发现高表达CD3、CD8,含有很低量的调节性T细胞(Treg),分泌大量的IFN γ,表明扩增出的细胞中活化T的含量很高,为临床研究提供参考。

参考文献/References:

［1］ Ryder S D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults［J］. Gut, 2003, 52(S 3): 1-8.
［2］ Roayaie  S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer≤2 cm: results from two western centers［J］. Hepatology, 2013, 57(4): 1426-1435.
［3］ Rapoport A P, Stadtmauer E A, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive Tcell transfer［J］. Nature Medicine, 2005, 11(11): 1230-1237.
［4］ Banchereau  J, Steinman R M. Dendritic cells and the control of immunity［J］. Nature, 1998, 392(6673): 245-252.
［5］ Steinman R M. The dendritic cell system and its role in immunogenicity［J］. Annual Review of Immunology, 1991, 9(1): 271-296.
［6］ Wu L, Dakic A. Development of dendritic cell system［J］. Cell Mol Immunol, 2004, 1(2): 112-118.
［7］ Sun K, Wang L, Zhang Y. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma［J］. Cell Mol Immunol, 2006, 3(3): 197-203.
［8］ Van  Brussel I, Berneman Z N, Cools N. Optimizing dendritic cell based immunotherapy: tackling the complexity of different arms of the Immune system［J］. Mediators of inflammation, 2012: 1-14.
［9］ Dudley  M E, Wunderlich J R, Robbins P F, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes［J］. Science, 2002, 298(5594): 850-854.
［10］ Laport G G, Levine B L, Stadtmauer E A, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation［J］. Blood, 2003, 102(6): 2004-2013.
［11］ Brentjens R J, Davila M L, Riviere I, et al. CD19targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia［J］. Science Translational Medicine, 2013, 5(177): 1-19.

备注/Memo

备注/Memo:
收稿日期： 2014-02-22
基金项目： 上海细胞治疗工程技术研究中心,上海工程技术研究中心课题(12DZ2251600)
作者简介： 郑竹影(1988-),女,江苏无锡人,硕士研究生,研究方向为肿瘤细胞治疗
通信作者： 钱其军,E-mail:qianqj@163.com
更新日期/Last Update: 2014-11-19